NEW YORK, Sept. 4 (GenomeWeb News) - Ira Marks has been named vice president, worldwide sales and marketing at Cepheid, the Sunnyvale, Calf.-based company said Sept. 3.
Marks, who will begin work on Sept. 8, comes to Cepheid from Nanogen, where he was senior vice president, corporate development and international operations.Before joining Nanogen, he was president of the Raichem division of Hemagen Diagnostics, and prior to that, held numerous positions at Bio-Rad laboratories.
Marks' appointment follows the naming June 30 of Joseph Smith as vice president and general counsel, and Russel Enns as vice president of regulatory and clinical affairs.
Claude Benchimol has been appointed senior vice president of research and development at Invitrogen, and John
Carrino has been promoted to chief scientist the company said Sept. 2.
Benchimol joins Invitrogen from General Electric, where he has served in various positions for the past 15 years-most recently as vice president and general manager of global technology for GE's Medical Systems, Information Technologies division.
Carrino previously served as vice president of R&D for Invitrogen, and previously has worked at Nanogen and Abbott Laboratories.
Yoichi Nishinakamura has been appointed chairman and CEO of the Otsuka Maryland Research Institute of Rockville, Md., the US clinical research and development subsidiary of Otsuka Pharmaceutical Co. of Japan, the company said Sept. 2.
Nishinakamura has previously worked at Otsuka Pharmaceutical in numerous leadership roles related to R&D, marketing, and pharmacovigilance. He led development of Otsuka's SNP-based products in Japan, the company said.
Klaus Dembowsky has been appointed vice president drug discovery of Ingenium Pharmaceuticals, the Munich-based company said Sept. 2.
Dembowsky joins Ingenium from a ten-year stint at Bayer, where he most recently managed the company's drug target discovery collaboration with Millennium. Prior to joining Bayer, Dembowsky served as associate professor of physiology at the University of Heidelberg.
Hans Johansson, currently president of Personal Chemistry, will become president and COO of Uppsala, Sweden-based Pyrosequencing, and Jon Sverre Schanche, vice president of R&D at Personal Chemistry, will be the vice president of R&D at Pyrosequencing, following the merger of the two companies at the end of September, the company said Aug. 27.
Additionally, Scott Carr, who heads up Personal Chemistry's American sales company, will become president of the merged US subsidiaries.
Erik Wallden, the current president of Pyrosequencing, will step down from his position effective at the company's merger, which is scheduled to take place September 25.
Ed Umali has been appointed director of operations, David Haen as director of business operations, and Carolyn French as director of communications atCytRx, the company said Aug. 26.
All three come from CEO Steve Kriegsman's investment firm, The Kriegsman Group.
French's position at CytRx is on a full-time basis, while Umali and Haen are expected to continue to provide certain services to The Kriegsman Group on a limited basis.
Richard Levy has joined Incyte as senior vice president, drug development, the company said Aug. 26.
Levy most recently served as vice president, biologic therapies at Celgene. Prior to that, he worked at vice president of regulatory affairs and pharmacovigilance, then as vice president of medical and commercial strategy, at DuPont.
Meanwhile, the Palo Alto, Calif., company said Aug. 22 that Robert Stein, president and chief scientific officer, had resigned his position "to take a senior position at a leading west coast life science company."
Catherine Burzik has been appointed executive vice president of Applied Biosystems, the company said Aug. 25.
Burzik comes to ABI from Ortho-Clinical Diagnostics, a Johnson & Johnson company, where she served as president. Prior to that, Burzik was general manager and vice president of Critikon, another Johnson & Johnson company,and has held executive positions at Eastman Kodak.
Julian Adams, senior vice president drug discovery and development at Millennium, is leaving the company to become chief scientific officer at Infinity Pharmaceuticals, the company said Aug. 22. The company is actively recruiting a replacement for Adams.